Gender-based violence screening methods preferred by women visiting a public hospital in Pune, India

Citation: Suryavanshi N, Naik S, Waghmare S, Gupte N, Khan S, Mave V, Deluca A, Gupta A, Golub J, Bollinger RC, Shankar A. Gender-based violence screening methods preferred by women visiting a public hospital in Pune, India. BMC Womens Health. 2018 Jan 15;18(1):19. doi: 10.1186/s12905-018-0515-2. PMID: 29334936. PMCID: PMC5769341.

Access full article:

https://www.ncbi.nlm.nih.gov/pubmed/29334936

Summary: 
Background: Gender-based violence (GBV) is a major global public health concern and is a risk factor for adverse health outcomes. Early identification of GBV is crucial for improved health outcomes. Interactions with health care providers may provide a unique opportunity for routine GBV screening, if a safe, confidential environment can be established.

Methods: Between November 2014 and February 2015, a cross-sectional, observational study was conducted where women were interviewed about their opinions concerning GBV screening in a tertiary health care setting in Pune, India. Trained counsellors interviewed 300 women at different out-patient and in-patient departments using a semi-structured questionnaire.

Results: Twenty-three percent of these women reported experiencing GBV in their life. However, 90% of women said they had never been asked about GBV in a health care setting. Seventy-two percent expressed willingness to be asked about GBV by their health care providers, with the preferred provider being nurses or counsellors. More than half (53%) women reported face-to-face interview as the most preferred method for screening. There were no major differences in these preferences by GBV history status.

Conclusions: Our study provides evidence for preferred GBV screening methods and optimal provider engagement as perceived by women attending a public hospital.

BMC Womens Health. 2018;18(1): e19

Categories

CRS
Topics

Clinical Trials

P1070, Dose-Finding and Pharmacogenetic Study of Efavirenz...

Efavirenz (EFV) is an anti-HIV medicine that is commonly used to treat HIV infection in adults and children older than 3 years...

Read More

The Pharmacokinetics, Safety and Acceptability of New...

PK, safety and acceptability data and practical guidance on the optimal dosing of new more child-friendly formulations of...

Read More

P2001 (DAIDS ID 12026): Evaluating the Pharmacokinetics,...

TB is a major cause of illness and death in women of reproductive age. Pregnant and postpartum women with latent TB are at...

Read More

P1077FF: Formula Feeding Version of the PROMISE Study...

1077FF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More

A5207, Maintaining Options for Mothers Study (MOMS): A Phase...

A major disadvantage of giving SD NVP is the potential for maternal development of NVP resistance and additional resistance to...

Read More